ENDOLOGIX INC's ticker is and the CUSIP is 29266SAA4. A total of 12 filers reported holding ENDOLOGIX INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $141,000 | -0.7% | 144,000 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $142,000 | +42.0% | 144,000 | +38.5% | 0.00% | +100.0% |
Q1 2018 | $100,000 | -1.0% | 104,000 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $101,000 | -96.8% | 104,000 | -96.8% | 0.00% | -97.9% |
Q3 2016 | $3,117,000 | -62.3% | 3,230,000 | -64.0% | 0.05% | -62.4% |
Q2 2016 | $8,263,000 | +25.8% | 8,967,000 | 0.0% | 0.12% | -33.2% |
Q1 2016 | $6,570,000 | -12.6% | 8,967,000 | 0.0% | 0.19% | +15.4% |
Q4 2015 | $7,519,000 | -4.9% | 8,967,000 | +2.1% | 0.16% | -13.4% |
Q3 2015 | $7,903,000 | -8.2% | 8,786,000 | 0.0% | 0.19% | -4.1% |
Q2 2015 | $8,607,000 | -3.2% | 8,786,000 | +0.1% | 0.20% | +10.2% |
Q1 2015 | $8,894,000 | +3.2% | 8,780,000 | 0.0% | 0.18% | +5.4% |
Q4 2014 | $8,619,000 | +12.0% | 8,780,000 | +1.8% | 0.17% | +4.3% |
Q3 2014 | $7,694,000 | -12.1% | 8,625,000 | 0.0% | 0.16% | -16.1% |
Q2 2014 | $8,757,000 | +5.7% | 8,625,000 | 0.0% | 0.19% | +8.5% |
Q1 2014 | $8,282,000 | – | 8,625,000 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Endurant Capital Management LP | 1,541,000 | $1,487,000 | 0.66% |
PALISADE CAPITAL MANAGEMENT, LP | 2,846,000 | $2,761,000 | 0.08% |
Citadel Advisors | 12,805,000 | $12,549,000 | 0.01% |
Capco Asset Management, LLC | 3,000 | $3,000 | 0.00% |
WOLVERINE ASSET MANAGEMENT LLC | 144,000 | $141,000 | 0.00% |
STIFEL FINANCIAL CORP | 58,237 | $58,000 | 0.00% |
CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
LADENBURG THALMANN FINANCIAL SERVICES INC. | 3,000 | $3,000 | 0.00% |
MORGAN STANLEY | 89,000 | $86,000 | 0.00% |